Inactive Instrument

Nuvo Pharmaceuticals Inc.

MRV

CA67092F1045

Nuvo Pharmaceuticals Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2021

March 28, 2022 at 07:37 am EDT

Nuvo Pharmaceuticals Inc. reported impairment for the fourth quarter ended December 31, 2021. For the quarter, the company reported impairment of $3,246 against $1,583 a year ago.

Latest news about Nuvo Pharmaceuticals Inc.

Searchlight Pharma Inc. completed the acquisition of Nuvo Pharmaceuticals Inc. from Red Oak Partners, LLC and other shareholders.	23-03-13	CI
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare Brief: Obtained Friday Final Order Approving Plan of Arrangement Related To Acquisition by Searchlight Pharma Inc.	23-03-13	MT
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare Brief: Announcing Shareholder Approval of Plan of Arrangement Related To Acquisition by Searchlight Pharma Inc.	23-03-07	MT
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare Up 88% After Entering into Definitive Agreement to be Acquired by Searchlight Pharma Inc.	22-12-28	MT
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare Entered into Definitive Agreement to be Acquired by Searchlight Pharma Inc.	22-12-28	MT
Searchlight Pharma Inc. entered into a definitive agreement to acquire Nuvo Pharmaceuticals Inc. from Red Oak Partners, LLC and other shareholders for CAD 15.4 million.	22-12-22	CI
Transcript : Nuvo Pharmaceuticals Inc., Q3 2022 Earnings Call, Nov 14, 2022	22-11-14
Miravo Healthcare Reports Q3 Results, Says Canadian Commercial Business Segment Continues to Grow	22-11-14	MT
Nuvo Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Earnings Flash (MRV) NUVO PHARMACEUTICALS Reports Q3 Revenue $18.1M	22-11-14	MT
Nuvo Pharmaceuticals Seeks Acquisitions	22-08-15	CI
Transcript : Nuvo Pharmaceuticals Inc., Q2 2022 Earnings Call, Aug 15, 2022	22-08-15
Miravo Healthcare Higher as Announces Q2 Revenue of $20.9 Million; to Wind Down Pennsaid 2% Quebec Facility	22-08-15	MT
Nuvo Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors	22-08-15	CI
Miravo Healthcare Brief: Q2 Total Revenue was C$20.9 Million; Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare	22-08-15	MT
North American Morning Briefing : Stock Futures -3-	22-08-15	DJ
Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to Its Board of Directors	22-05-24	CI
Transcript : Nuvo Pharmaceuticals Inc., Q1 2022 Earnings Call, May 16, 2022	22-05-16
Nuvo Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
North American Morning Briefing : Stock Futures -3-	22-05-16	DJ
Nuvo Pharmaceuticals Inc. Provides an Update on the United States Pennsaid® 2% Business	22-05-12	CI
Transcript : Nuvo Pharmaceuticals Inc., Q4 2021 Earnings Call, Mar 28, 2022	22-03-28
Nuvo Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Nuvo Pharmaceuticals Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2021	22-03-28	CI

Chart Nuvo Pharmaceuticals Inc.

Duration

Period

More charts

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, is a Canada-based healthcare company. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. Its segments include Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment offers products with promotional efforts, such as Blexten, Cambia, Suvexx and NeoVisc , as well as a number of mature products. The Production and Service Business segment includes the sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the licensing of intellectual property and ongoing royalties from licensing agreements.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals